Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
Revive Therapeutics provide an update on the Company’s U.S.FDA Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of Bucillamine in COVID-19.